Literature DB >> 1101933

Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.

G P Canellos, V T DeVita, R C Young, B A Chabner, P S Schein, R E Johnson.   

Abstract

The initial results of a randomized clinical trial comparing intensive cyclical combination chemotherapy (CVP) and total body radiation therapy in the treatment of advanced (Stage III and IV) lymphocytic lymphoma is presented. Sixty-five patients have been entered and randomized according to stage. Of the chemotherapy treated patients, (22/27 (81%) achieved a response with 55% complete responders. The radiation group or those treated with radiation 27/32 (84%) responded with 56% in complete response. There is no significant difference in overall survival between the two groups. Nodular lymphoma (44 patients) responds more often and has s significantly longer survival than diffuse lymphoma (21 patients). Approximately 50% of the complete remitters have relapsed but reinduction of disease control was possible in almost all cases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101933      PMCID: PMC2149565     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  8 in total

1.  Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata.

Authors:  B A Chabner; R E Johnson; P B Chretien; P S Schein; R C Young; C P Canellos; S H Hubbard; T Anderson; S H Rosenoff; V T DeVita
Journal:  Br J Cancer Suppl       Date:  1975-03

2.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Remission induction and remission duration with primary radiotherapy in advanced lymphosarcoma.

Authors:  R E Johnson
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.

Authors:  J K Luce; J F Gamble; H E Wilson; R W Monto; B L Isaacs; R L Palmer; C A Coltman; J S Hewlett; E A Gehan; E Frei
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

5.  Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids.

Authors:  P P Carbone; C Spurr; M Schneiderman; J Scotto; J F Holland; B Shnider
Journal:  Cancer Res       Date:  1968-05       Impact factor: 12.701

6.  Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

Authors:  C M Bagley; V T Devita; C W Berard; G P Canellos
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

7.  Primary management of advanced lymphosarcoma with radiotherapy.

Authors:  R E Johnson; G T O'Conor; D Levin
Journal:  Cancer       Date:  1970-04       Impact factor: 6.860

8.  Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.

Authors:  B Hoogstraten; A H Owens; R E Lenhard; O J Glidewell; L A Leone; K B Olson; J B Harley; S R Townsend; S Miller; C L Spurr
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

  8 in total
  3 in total

Review 1.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

2.  Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification.

Authors:  K Musshoff; H Schmidt-Vollmer
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975-08-08

3.  Management of generalized malignant lymphomata with "systemic" radiotherapy.

Authors:  R E Johnson
Journal:  Br J Cancer Suppl       Date:  1975-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.